Animal studyReported positivePreclinical onlyTier 2 · animaln = 72
Gynecologic oncology · Jun 2025 · archival tissue analysis plus patient-derived organoid and xenograft preclinical study
This study looked at TROP2 levels in uterine carcinosarcoma samples and tested the TROP2-targeting antibody-drug conjugate sacituzumab govitecan in patient-derived organoid and xenograft models. Most tumors had detectable TROP2, and the organoid models responded to the drug in a dose-dependent way. In two xenograft models, tumor volume was lower with sacituzumab govitecan than without it.
Reported effects: TROP2 expression in primary UCSs 90%, n=72 · Higher TROP2 expression by histologic subtype, p p < 0.001 and p = 0.022, n=72 · +2 more
Key findings
- TROP2 protein and mRNA were detected in at least 90% of primary uterine carcinosarcomas.
- Tumors with a predominant carcinomatous component or homologous differentiation had higher TROP2 expression than those with predominant sarcomatous component or heterologous differentiation.
- All 9 uterine carcinosarcoma organoid models responded in a dose-dependent manner to sacituzumab govitecan.
- Both xenograft models showed significant reduction in tumor volume with sacituzumab govitecan.
Limitations: Preclinical study; findings are from archival tissues, organoids, and mouse xenografts, not patients.; Only 2 xenograft models were tested.; No clinical outcomes, safety data, or survival data in humans were reported.; The abstract does not provide dosing details or treatment duration..
Supports preclinical exploration of TROP2-targeted therapy in uterine carcinosarcoma.
AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed · Full text
ReviewInconclusiveModerate evidenceTier 4 · clinical
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society · Jan 2021
Endometrial carcinoma
European specialist societies (ESGO, ESTRO, ESP) updated prior 2014 consensus guidelines for the management of endometrial carcinoma. The update was undertaken because of a large body of new literature and aims to cover new topics and improve quality of care for women with endometrial carcinoma across Europe and worldwide.
Key findings
- A 2014 European consensus conference previously produced multidisciplinary evidence-based guidelines on endometrial carcinoma.
- ESGO, ESTRO, and ESP jointly decided to update these evidence-based guidelines given the large volume of literature since 2014.
- The update intends to cover new topics and to improve the quality of care for women with endometrial carcinoma across Europe and worldwide.
Limitations: Abstract gives no details of methods used for the guideline update (search strategy, evidence grading, or consensus process).; No specific recommendations, guidance statements, or levels of evidence are reported in the abstract.; Not a primary research study — no new patient-level data, outcomes, or quantitative results are presented in the abstract..
AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed
Human · observationalMechanismMixed resultsModerate evidenceTier 3 · early humann = 373
Nature · May 2013 · Integrated genomic, transcriptomic and proteomic characterization
endometrial carcinomauterine serous carcinomaendometrioid tumourovarian serous carcinomabasal-like breast carcinoma
The authors performed integrated genomic, transcriptomic and proteomic analyses of 373 endometrial carcinomas. They identified four molecular subtypes (POLE ultramutated, microsatellite instability hypermutated, copy-number low, and copy-number high) with distinct mutation and copy-number profiles. Uterine serous and about 25% of high-grade endometrioid tumors had many copy-number alterations and frequent TP53 mutations, while most endometrioid tumors had frequent PTEN, CTNNB1, PIK3CA, ARID1A and KRAS mutations and novel ARID5B alterations. The authors note that this genomic classification may affect post-surgical adjuvant treatment decisions for women with aggressive tumors.
Reported effects: sample_size 373, n=373 · proportion_high-grade_endometrioid_with_extensive_copy_number_alterations 25% · +1 more
Key findings
- Integrated analysis of 373 endometrial carcinomas was performed using array- and sequencing-based technologies.
- Uterine serous tumours and ∼25% of high-grade endometrioid tumours had extensive copy number alterations, few DNA methylation changes, low estrogen/progesterone receptor levels, and frequent TP53 mutations.
- Most endometrioid tumours had few copy number alterations or TP53 mutations, but frequent mutations in PTEN, CTNNB1, PIK3CA, ARID1A and KRAS and novel mutations in ARID5B.
- A subset of endometrioid tumours had a markedly increased transversion mutation frequency and newly identified hotspot mutations in POLE.
- Endometrial cancers were classified into four categories: POLE ultramutated, microsatellite instability hypermutated, copy-number low, and copy-number high.
- Uterine serous carcinomas share genomic features with ovarian serous and basal-like breast carcinomas.
Limitations: Observational genomic characterization of tumor samples without interventional or longitudinal clinical trial data.; No clinical outcome or treatment-response data reported in the abstract to validate proposed treatment implications.; Functional consequences of newly identified mutations (e.g., ARID5B, POLE hotspots) are not demonstrated in this report.; Cohort is limited to 373 tumors; subgroup counts and generalizability to all patient populations are not detailed in the abstract..
AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed · Full text
ReviewMechanismInconclusiveLimited evidenceTier 4 · clinical
Annual review of pathology · Jan 2007
endometrial carcinoma
This review summarizes current molecular understanding of endometrial carcinoma. It states that endometrial carcinoma comprises multiple tumor types with distinct microscopic features, molecular genetic alterations, and prognoses. The abstract notes that hormonal influences interact with genetic alterations to affect growth-regulatory pathways. The authors highlight progress from clinicopathological studies, molecular analyses, and animal studies toward identifying fundamental pathways involved in development and progression.
Key findings
- Endometrial carcinoma is composed of multiple tumor types with different light-microscopic features, molecular genetic alterations, and prognoses.
- Hormonal influences significantly impact growth regulatory pathways and interact with genetic alterations in the pathogenesis of some types of endometrial carcinoma.
- Awareness of the different tumor types and use of clinicopathological studies, molecular analyses, and animal studies have increased understanding of the biological underpinnings.
- The review presents current understanding from a molecular vantage, highlighting pathways thought to be fundamental in development and progression of major types.
Limitations: Review article — contains synthesis of prior work and presents no new primary data.; Heterogeneity of endometrial tumor types complicates analyses and generalization.; Conclusions are partly based on animal studies, which may not fully translate to humans.; Abstract does not present quantitative results or detailed pathway data..
AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed